Shots:

•  The P-IV AUGUSTUS study involves assessing of Eliquis (apixaban) vs vitamin K antagonists (VKAs) & aspirin vs PBO in 4-614 patients with non-valvular atrial fibrillation (NVAF)- acute coronary syndrome (ACS) & undergoing percutaneous coronary intervention (PCI) with P2Y12 inhibitor with or without aspirin
• The P-IV AUGUSTUS study results: low mortality rate (23.5% vs 27.4% & 26.2% vs 24.7%); ischemic events (6.7% vs 7.1% & 6.5% vs 7.3%); CRNM bleeding (10.5% vs 14.7% & 16.1% vs. 9.0%)
• Eliquis (apixaban-5mg/2.5mg- q2d) is an oral anticoagulant targeting factor Xa inhibitor to prevent thromboembolic event and has received FDA’s approval on December 28- 2012 & August 21- 2014 for atrial fibrillation & recurring DVT and PE respectively

Click here to read full press release/ article

Ref: BMS | Image: BMS